Publications:Duffy NA, Green BD, Irwin N, Gault VA, McKillop AM, O'Harte FP, Flatt PR; Effects <strong>of</strong> antidiabetic drugs on dipeptidylpeptidase IV activity: Nateglinide is an inhibitor <strong>of</strong> DPP IV and augments the antidiabetic activity <strong>of</strong> glucagon-likepeptide-1; European Journal <strong>of</strong> Pharmacology, 568: 278-286, 2007Gault VA, Hunter K, Irwin N, Green BD, Greer B, Harriott P, O'Harte FP, Flatt PR; Characterisation and biological activity<strong>of</strong> Glu 3 amino acid substituted GIP receptor antagonists; Archives <strong>of</strong> Biochemistry Biophysics, 461: 263-274, 2007Gault VA, McClean PL, Irwin N, Power GJ, McCluskey JT, Flatt PR; Effects <strong>of</strong> subchronic treatment with the long-actingglucose-dependent insulinotropic polypeptide receptor agonist, N-AcGIP, on glucose homeostasis in streptozotocininduceddiabetes; Pancreas, 35: 73-79, 2007Gault VA, McClean PL, Cassidy RS, Irwin N, Flatt PR; Chemical gastric inhibitory polypeptide receptor antagonismprotects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high-fat andcafeteria diets; Diabetologia, 50: 1752-1762, 2007Green BD, Irwin N, Flatt PR; Direct and indirect effects <strong>of</strong> obestatin peptides on food intake and the regulation <strong>of</strong>glucose homeostasis and insulin secretion in mice; Peptides, 28: 981-987, 2007Irwin N, McClean PL, Cassidy RS, O'Harte FP, Green BD, Gault VA, Harriott P, Flatt PR; Comparison <strong>of</strong> the antidiabeticeffects <strong>of</strong> GIP- and GLP-1-receptor activation in obese diabetic (ob/ob) mice: studies with DPP IV resistantN-AcGIP and exendin(1-39)amide; Diabetes Metabolism <strong>Research</strong> and Reviews, 23: 572-579, 2007Irwin N, Hunter K, Flatt PR; Comparison <strong>of</strong> the metabolic effects <strong>of</strong> GIP receptor antagonism and PYY(3-36) receptoractivation in high fat fed mice; Peptides, 28: 2192-2198, 2007Irwin N, McClean PL, O'Harte FP, Gault VA, Harriott P, Flatt PR; Early administration <strong>of</strong> the glucose-dependent insulinotropicpolypeptide receptor antagonist (Pro( 3 ))GIP prevents the development <strong>of</strong> diabetes and related metabolicabnormalities associated with genetically inherited obesity in ob/ob mice; Diabetologia, 50: 1532-1540, 2007Irwin N, McClean PL, Flatt PR; Comparison <strong>of</strong> the subchronic antidiabetic effects <strong>of</strong> DPP IV-resistant GIP and GLP-1analogues in obese diabetic (ob/ob) mice; Journal <strong>of</strong> Peptide Science, 13: 400-405, 2007Irwin N, McClean PL, Harriott P, Flatt PR; Beneficial effects <strong>of</strong> sub-chronic activation <strong>of</strong> glucagon-like peptide-1 (GLP-1) receptors on deterioration <strong>of</strong> glucose homeostasis and insulin secretion in aging mice; Experimental Gerontology,42: 296-300, 2007McClean PL, Irwin N, Cassidy RS, Holst JJ, Gault VA, Flatt PR; GIP receptor antagonism reverses obesity, insulin resistanceand associated metabolic disturbances induced in mice by prolonged consumption <strong>of</strong> high fat diet; AmericanJournal <strong>of</strong> Physiology Endocrinology and Metabolism, 293: E1746-1755, 2007O'Harte FP, Hunter K, Gault VA, Irwin N, Green BD, Greer B, Harriott P, Bailey CJ, Flatt PR; Antagonistic effects <strong>of</strong>two novel GIP analogues, (Hyp 3 )GIP and (Hyp 3 )GIPLys 16 PAL on the biological actions <strong>of</strong> GIP and longer term effectsin diabetic ob/ob mice; American Journal <strong>of</strong> Physiology Endocrinology and Metabolism, 292: E1674-1682, 2007Gault VA, Kerr BD, Irwin N, Flatt PR; C-terminal mini-PEGylation <strong>of</strong> glucose-dependent insulinotropic polypeptideexhibits metabolic stability and improved glucose homeostasis in dietary-induced diabetes; Biochemical Pharmacology,75: 2325-2333, 2008Irwin N, McClean PL, Hunter K, Gault VA & Flatt PR (Pro 3 )GIP[mPEG]: Novel long-acting mini-PEGylated gastricinhibitory polypeptide antagonist for obesity-diabetes therapy; British Journal <strong>of</strong> Pharmacology, 155: 690-701, 2008Irwin N, Hunter K, Flatt PR; Comparison <strong>of</strong> independent and combined chronic metabolic effects <strong>of</strong> GIP and CB 1receptor blockade in high-fat fed mice; Peptides, 29: 1036-1041, 200854
Irwin N, Hunter K, Frizzell N, Flatt PR; Antidiabetic effects <strong>of</strong> sub-chronic administration <strong>of</strong> the cannabinoid receptor(CB 1) antagonist, AM251, in obese diabetic (ob/ob) mice; European Journal <strong>of</strong> Pharmacology, 581: 226-233, 2008Irwin N, Cassidy RS, Flatt PR; Effects <strong>of</strong> Gastric Inhibitory Polypeptide (GIP) and related analogues on glucagon releaseat normo- and hyper-glycaemia in wistar rats and isolated islets; Biological Chemistry, 389: 189-193, 2008McClean PL, Gault VA, Irwin N, McCluskey JT and Flatt PR; Daily administration <strong>of</strong> the GIP-R antagonist (Pro 3 )GIP instreptozotocin-induced diabetes suggests insulin-dependent mechanisms are critical to anti-obesity-diabetes actions<strong>of</strong> (Pro 3 )GIP; Diabetes Obesity and Metabolism, 10: 336-342, 2008Taylor A, Irwin N, McKillop AM, Flatt PR, Gault VA; Sub-chronic administration <strong>of</strong> 11beta-HSD1 inhibitor, carbenoxolone,improves glucose tolerance and insulin sensitivity in mice with diet-induced obesity; Biological Chemistry, 389:441-445, 2008Irwin N, McClean PL, Hunter K & Flatt PR; Metabolic effects <strong>of</strong> sustained activation <strong>of</strong> the GLP-1 receptor alone andin combination with background GIP receptor antagonism in high fat fed mice. Diabetes, Obesity and Metabolism(in press)Irwin N, Hunter K, Frizzell N & Flatt PR (2009) Antidiabetic effects <strong>of</strong> sub-chronic activation <strong>of</strong> the GIP receptoralone and in combination with background exendin-4 therapy in high fat fed mice. Regulatory Peptides (in press)55
- Page 1:
BIOMEDICAL SCIENCESRESEARCH INSTITU
- Page 4 and 5:
1 Foreword by the Pro Vice-Chancell
- Page 6 and 7: 2 Foreword by the Research Institut
- Page 8 and 9: The BMSRI Research StructureThe BMS
- Page 10 and 11: BMSRI Core FacilitiesContact: Karen
- Page 12 and 13: of Metabolomics, pharmacy, nutritio
- Page 14 and 15: BMSRI Academic Heads new Regional N
- Page 16 and 17: 4. BIOMEDICAL GENOMICS RESEARCH GRO
- Page 18 and 19: Recent Funding Initiatives:C-TRIC:
- Page 20 and 21: Dr Mateus Webba da SilvaLecturer in
- Page 22 and 23: 5. BIOIMAGING RESEARCH GROUPResearc
- Page 24 and 25: developmental alterations that mani
- Page 26 and 27: Publications:Bigot S, Lucas L, Morr
- Page 28 and 29: Publications:Barnes CA, O’Hagan B
- Page 30 and 31: We also measure the genotoxic effec
- Page 32 and 33: 6. CANCER AND AGEING RESEARCH GROUP
- Page 34 and 35: Professor Anthony P McHaleProfessor
- Page 36 and 37: Professor Stephanie McKeownProfesso
- Page 38 and 39: an Alzheimer Research Trust collabo
- Page 40 and 41: JM, Waugh DJJ; Dexamethasone potent
- Page 42 and 43: have wider applications in vivo, in
- Page 44 and 45: Inter-relationships between diet an
- Page 46 and 47: Flatt PR; Effective surgical treatm
- Page 48 and 49: These areas are the subject of seve
- Page 50 and 51: Dr YHA Abdel-WahabSenior Lecturer i
- Page 52 and 53: Dr VA GaultLecturer in Molecular Bi
- Page 54 and 55: McClean PL, Irwin N, Hunter K, Gaul
- Page 58 and 59: 8. MICROBIOLOGY AND BIOTECHNOLOGYRE
- Page 60 and 61: Publications:Graham RJL, Graham C,
- Page 62 and 63: analyses. However there is still a
- Page 64 and 65: Plessas S, Bekatorou A, Koutinas AA
- Page 66 and 67: Biochemical studies/ viral evasion
- Page 68 and 69: Dr Stephen McCleanLecturer in Prote
- Page 70 and 71: environmental remediation and as ro
- Page 72 and 73: 9. NORTHERN IRELAND CENTRE FOR FOOD
- Page 74 and 75: 26-28 Sept 2007: International Seaf
- Page 76 and 77: Dr Barnes has developed expertise i
- Page 78 and 79: Dr Alison GallagherSenior Lecturer
- Page 80 and 81: In addition, results of a pilot stu
- Page 82 and 83: Dr Maeve KerrResearch AssociateCont
- Page 84 and 85: Memberships of External Committees/
- Page 86 and 87: Indicators of Esteem:Professor McNu
- Page 88 and 89: were examined. The intervention and
- Page 90 and 91: Within this work both short-term an
- Page 92 and 93: micronutrient supplementation at a
- Page 94 and 95: 10. STEM CELL & EPIGENETICS RESEARC
- Page 96 and 97: Publications:Lees-Murdock DJ, Lau H
- Page 98 and 99: Publications:Lees-Murdock DJ, Lau H
- Page 100 and 101: 11. SYSTEMS BIOLOGY RESEARCH GROUPT
- Page 102 and 103: Kravtsov V, Swain M, Schuster A, Du
- Page 104 and 105: Dr Daniel BerrarLecturer in Biomedi
- Page 106 and 107:
Zhang et al; Incorporating Feature
- Page 108 and 109:
Bala P, Baldridge K, Benfenati E, C
- Page 110 and 111:
In addition there is a growing them
- Page 112 and 113:
Clinical work involves development
- Page 114 and 115:
In 2009 he was appointed Chairman o
- Page 116 and 117:
Stevenson TR, Goodall EA and Moore
- Page 118 and 119:
Dr Raymond BeirneLecturer in Optome
- Page 120 and 121:
Dr Julie McClellandLecturer in Opto
- Page 122 and 123:
Graham JE, Moore JE, Moore JE, McCl
- Page 124 and 125:
Research Staff:Dr David OrrSenior R
- Page 126 and 127:
Dr Victoria McGilliganResearch Asso
- Page 128 and 129:
13. Externally Funded Projects duri
- Page 130 and 131:
Grant Holder Anderson, Prof RSFundi
- Page 132 and 133:
Funding Body Royal Irish AcademyAmo
- Page 134 and 135:
14. BIOMEDICAL SCIENCES RESEARCH IN
- Page 136 and 137:
Student: Simon GenglerTitle: Effect
- Page 138 and 139:
Student: Anisha MazumdarTitle: Anal
- Page 140 and 141:
Student: Clare RyanTitle: How does
- Page 142 and 143:
CONGRATULATIONS TO THE FOLLOWING PO
Change language